Core Points - The 2025 Annual General Meeting of Compagnie Financière Richemont SA was held in Geneva, where all agenda items were approved by shareholders [2] - An ordinary dividend of CHF 3.00 per 'A' share and CHF 0.30 per 'B' share was approved, subject to Swiss withholding tax at 35% [3][4] - The remaining retained earnings after the dividend payment will be carried forward to the next business year [3] Dividend Payment Details - The dividend for 'A' shares traded on the SIX Swiss Stock Exchange is expected to be paid on 22 September 2025, while the payment for 'A' shares on the Johannesburg Stock Exchange will be on 29 September 2025 [4] - The rand amount for the Johannesburg Stock Exchange will be based on the exchange rate published on 10 September 2025 [4] Corporate Governance - The Non-Financial Report was approved by shareholders in compliance with Swiss law [5] - All Board members standing for re-election were re-elected for another one-year term [5] - Wendy Luhabe was designated as the representative of 'A' shareholders on the Board and re-elected [6] - KPMG SA was appointed as the new auditor, replacing PricewaterhouseCoopers, for a term of one year [6] Additional Information - Detailed voting results and the Chairman's address will be available for download on the Richemont website [7] - Richemont operates in three business areas: Jewellery Maisons, Specialist Watchmakers, and Fashion & Accessories Maisons [9] - Richemont 'A' shares are listed on the SIX Swiss Exchange and included in the Swiss Market Index [10]

Core Insights - ECARX Holdings Inc. has launched a next-generation in-vehicle navigation system and the latest version of its Skyland New intelligent driving solution at IAA Mobility 2025 in Munich, highlighting its commitment to an innovative and scalable technology roadmap [1][4] Group 1: Navigation System - The new global navigation system is integrated with HERE's advanced navigation platform, designed for rapid integration and adaptability across more than 200 countries, ensuring compliance with international data regulations [2] - HERE's map data is utilized in over 222 million vehicles globally, supporting ECARX's goal to shorten automaker development cycles while adhering to regional regulatory requirements [2] - The navigation solution is currently supporting models from various automakers including Lotus, Lynk & Co, smart, and Hongqi, providing dynamic and personalized navigation experiences [2] Group 2: Intelligent Driving Solution - The latest iteration of the Skyland New intelligent driving solution utilizes a single system-on-a-chip architecture based on Black Sesame's Wudang C1236 chip, offering L2+ assisted driving and parking features [3] - Key features include map-free highway Navigate-on-Autopilot (NOA), Automatic Parking Assist (APA), and Remote Parking Assist (RPA), designed for cost-effective performance and seamless integration [3] - The Skyland solution, based on Black Sesame's Huashan A1000, is set to launch on the new Hongqi H9, H9+, and E-HS9 models by late 2025 [3] Group 3: Company Overview - ECARX is a global automotive technology provider that delivers full-stack solutions for next-generation smart vehicles, including system on a chip (SoC), central computing platforms, and software [5] - Founded in 2017 and listed on Nasdaq in 2022, ECARX employs over 1,600 people across 13 major locations worldwide [6] - The company has partnerships with notable automakers such as Volkswagen Group, FAW Group, and Dongfeng Peugeot-Citroën, with its products present in over 9.3 million vehicles globally [6]

ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF bispecifics DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK) (“ImmuneOnco ...

Core Insights - Immuneering Corporation plans to announce updated overall survival data for first-line pancreatic cancer patients treated with atebimetinib + mGnP on September 25, 2025, following a 9-month median follow-up [1][3][6] - The company has reported a 94% overall survival (OS) rate at 6 months for patients treated with atebimetinib + mGnP, compared to 67% OS for standard care, which drops to approximately 47% by 9 months [3][6] - Immuneering is developing a new category of cancer medicines called Deep Cyclic Inhibitors, with atebimetinib being the lead candidate currently in a Phase 2a trial [4][6] Company Plans and Presentations - An investor call is scheduled for 8 a.m. ET on September 25, 2025, to discuss the updated data [1][6] - Immuneering will present a poster on "Atebimetinib + mGnP: Overall Survival and Safety in First Line Pancreatic Cancer Patients" at the PanCAN Scientific Summit on September 28, 2025 [6] - The company will also present preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit on September 17, 2025 [5][6]

TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Carlton Precious Inc. (TSX-V: CPI | OTCQB: CPIFF) ("Carlton" or the "Company") is pleased to announce that effective today, the Company's common shares now trade in the United States on the OTC market under the new ticker symbol "CPIFF". The change from the previous symbol "NBRFF" to "CPIFF" is part of the Company's ongoing efforts to align its U.S. market identity with its current corporate name and TSX Venture Exchange ticker, "CPI". No action is required by exi ...

PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR) observed among 97 evaluable patients across all cohorts with a median duration of response of 6.2 months43% ORR observed among 44 evaluable patients in ovarian cancer cohort with a median duration of response of 7.6 monthsRezatapopt New Drug Application submiss ...

WARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the first U.S. surgical procedures with the VerteGlide Spinal Growth Guidance System (“VerteGlide”), used to treat Early Onset Scoliosis (“EOS”). Dr. Richard McCarthy, a pediatric orthopedic spine surgeon in Louisville, Kentucky who, along with Dr. Kent Walker, performed one ...

Albion Enterprise VCT PLC Interim Management Statement LEI Code: 213800OVSRDHRJBMO720 Introduction I present Albion Enterprise VCT PLC (the “Company”)’s interim management statement for the period from 1 April 2025 to 30 June 2025. Performance and dividends The Company's unaudited net asset value (“NAV”) on 30 June 2025 was £277.3 million or 115.72 pence per share (excluding treasury shares), a decrease of 0.50 pence per share (0.4%) since 31 March 2025. After accounting for the first dividend for the year ...

U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable MarketLONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® MagIQ™ injectable hyaluronic acid (“HA”) gel, the first product in the Obagi® saypha® collection under t ...

Core Viewpoint - Swiss Properties Invest has reported a positive performance in the first half of 2025, with expectations for continued growth and strong returns on investment over the long term [1][2]. Financial Performance - Group revenue for H1 2025 reached DKK 18.7 million, an increase from DKK 16.8 million in H1 2024 [5]. - Group operating profit for H1 2025 was DKK 11.8 million, compared to DKK 11.4 million in H1 2024 [5]. - Profit after tax for the group in H1 2025 was DKK 7.8 million, up from DKK 6.0 million in H1 2024 [5]. Interest Rate Impact - The Swiss National Bank has reduced interest rates twice in the first half of 2025, which is expected to positively impact the financial costs for Swiss Properties Invest, as these are the company's largest expenses [2]. Company Overview - Swiss Properties Invest A/S was founded on October 8, 2021, and serves as the Danish holding company for Swiss Properties Invest AG, established on December 7, 2021 [3]. - The company focuses on owning, operating, optimizing, and developing a portfolio of commercial properties in selected regions of Switzerland, aiming to create shareholder value [3]. Future Outlook - The management team expresses strong confidence in delivering on IPO promises, projecting a return on investment of at least 100% after 10 years and 300% after 20 years [2].